PT-141 research: what the published studies show

Receptor Pharmacology and Preclinical Work

PT-141 is a synthetic peptide analogue of alpha-MSH, and an agonist at melanocortin receptors including MC3R and MC4R, which are expressed primarily in the central nervous system.^[1]

Administration to rats and to nonhuman primates was reported to result in penile erections.^[1] Systemic administration to rats activated neurons in the hypothalamus, shown by increased c-Fos immunoreactivity.^[1] Neurons in that same region take up pseudorabies virus injected into the corpus cavernosum of the rat penis.^[1]

Two qualifications belong with this source. Its authors were affiliated with Palatin Technologies, the company developing the compound.^[1] Its conclusion is hedged as promise: the results suggest that PT-141 holds promise for sexual dysfunction, which states a prospect rather than a demonstrated effect.^[1]

The RECONNECT Phase 3 Trials

Two identical phase 3 randomized, double-blind, placebo-controlled multicenter trials were conducted in premenopausal women with hypoactive sexual desire disorder, the condition the trials enrolled for.^[2] Participants were randomized 1:1 to 24 weeks of bremelanotide 1.75 mg subcutaneously as needed, or placebo.^[2] Of 1,267 women randomized, 1,247 were in the safety population and 1,202 in the modified intent-to-treat efficacy population.^[2] Most participants were white, at 85.6%, from United States sites, at 96.6%, with a mean age of 39 years.^[2]

The coprimary endpoints were change from baseline to end of study on the Female Sexual Function Index desire domain, and on item 13 of the Female Sexual Distress Scale-Desire/Arousal/Orgasm.^[2] Both trials reported statistically significant increases in desire, with the change versus placebo at 0.30 in study 301 and 0.42 in study 302, and 0.35 integrated across both.^[2] Both trials also reported statistically significant reductions in desire-related distress, at -0.37 in study 301 and -0.29 in study 302, and -0.33 integrated.^[2]

A later integrated analysis of the same two trials examined 1,202 patients across prespecified subgroups.^[3] Those subgroups were age, weight, body mass index and bioavailable testosterone quartile.^[3] It reported statistically significant changes on both instruments across those subgroups, with few exceptions.^[3] It shares most of its authors with the primary report and covers no new participants.^[3]

The Open-Label Extension

Women who completed the 24-week double-blind phase without a serious adverse event could enter a 52-week open-label extension.^[4] Of 856 eligible patients, 684 enrolled and 272 completed it.^[4] That completion rate, under a third of those eligible, is part of the result.^[4]

All statistical analyses in the extension were descriptive, and no placebo comparison was carried forward.^[4] The most common treatment-emergent adverse events considered related to study drug were nausea at 40.4%, flushing at 20.6%, and headache at 12.0%.^[4] Nausea was the only severe such event experienced by more than one participant in both studies.^[4] The authors report that no new safety signals were observed.^[4]

An independent 2020 review gives adverse event rates from the trial program as nausea 39.9%, facial flushing 20.4% and headache 11%.^[5] It describes dosing as no more than one dose in 24 hours and no more than eight doses per month, with discontinuation recommended after eight weeks without benefit.^[5] That review also states plainly that although the trials met statistical significance on their endpoints, the clinical benefit may only be modest.^[5]

A Published Critique of the Efficacy Measures

A 2024 review in the Journal of Sex Research examined the measurement properties of the RECONNECT efficacy instruments, and its findings sit directly against the trial reports above.^[6]

It examined four continuous efficacy outcomes: the Female Sexual Function Index, its desire domain, the FSDS-DAO, and item 13 of that scale.^[6] All four, it reports, have questionable validity evidence at best for women with this condition.^[6]It found no validity evidence for the categorical treatment response outcomes previously published from those trials.^[6]

Its second finding concerns which results were published.^[6] Of the 11 efficacy outcomes registered on clinicaltrials.gov, 8 were previously unpublished, including the FSDS-DAO total score, the FSFI total score and the FSFI arousal domain.^[6]The authors analyzed those outcomes themselves and report effect sizes ranging from nil to small.^[6] Several other outcomes generated modest apparent benefits, but nearly all of those were likely derived post-hoc.^[6]

Its overall conclusion draws on the two prior publications and its own analysis.^[6] The benefits are statistically modest, and limited to outcomes for which scant validity evidence exists in this population.^[6]

State of the Evidence

The clinical record for this compound is unusually complete, and unusually contested.

Three of the six references report the same two trials: the primary report,^[2] the subgroup analysis^[3] and the open-label extension.^[4] All three share most of their authors and were funded by the developer. The 2020 review^[5] and the 2024 critique^[6] are independent of the sponsor. Weighting the record by publication count would overstate how much independent evidence exists.

The preclinical source is a 2003 paper from the developer's own scientists, and it hedges its conclusion as promise rather than demonstration.^[1] The strongest efficacy claims and the strongest methodological criticism both concern the same 24-week dataset.

Two things are worth stating precisely. The trials measured change on named instruments over 24 weeks, not any broader outcome.^[2] The published critique disputes whether those instruments measure what they are taken to measure in this population.^[6] That is a challenge to the endpoints, not to the statistics computed from them.